Current strategies for diagnosis and treatment of Clostridium difficile-infection (literature review)
https://doi.org/10.29413/ABS.2018-3.1.5
Abstract
The incidence and mortality rate of C. difficile infection (CDI) has increased remarkably over the last 10-20 years. CDI is a leading cause of healthcare-associated infections and antibiotic-associated diarrhoea. Increasing incidence and severity of CDI may be related with frequent antibiotic use and the emergence of a hypervirulent C. difficile strain. The epidemic strain NAP1 / BI / ribotype 027 is more resistant to antibiotics and produces more toxins and causes outbreaks around the world with increasing mortality and severity. Recent reports have documented that C. difficile infections occur among patients without traditional risk factors and the incidence of community-acquired CDI has increased. The clinical presentation of CDI ranging from the asymptomatic carrier to pseudomembranous colitis and toxic megacolon. The rate of recurrent CDI is 20-30 %. Early surgical consultation should be considered in all patients with severe or fulminant CDI. The preferred method for diagnosis CDI is stool testing using enzyme immunoassay (EIA) screening to look for glutamate dehydrogenase (GDH) antigen and toxins A and B. Metronidazole and vancomycin are recommended antibiotics for the treatment of CDI. Novel approaches include fidaxomicin therapy, monoclonal antibodies, and fecal microbiota transplantation. Fecal microbiota transplantation has shown relevant efficacy to overcome C. difficile infection and reduce it.
About the Authors
I. V. Nikolaeva
Kazan State Medical University
Russian Federation
Russian Federation
I. V. Shestakova
Moscow State University of Medicine and Dentistry named after A.I. Yevdokimov
Russian Federation
Russian Federation
G. K. Murtazina
Kazan State Medical University
Russian Federation
Russian Federation
References
1. Алексеечкина О.А., Дубров Э.Я., Владимирова Е.С., Пинчук Т.П., Титова Г.П. Возможности ультразвукового исследования в диагностике псевдомембранозного колита у хирургических больных // Российский журнал гастроэнтерологии, гепатологии и колопроктологии. - 2012. - № 2. - С. 29-35
2. Алёшкин В.А., Селькова Е.П., Миронов А.Ю., Гренкова Т.А., Шелыгин Ю.А., Сухина М.А., Ачкасов С.И., Сафин А.Л. Лабораторная диагностика Clostridium difficile-ассоциированных диарей. Федеральные клинические рекомендации. - М., 2017. - 24 с
3. Волчкова Е.В., Белоусова Е.А., Макарчук П.А., Русанова Э.В., Великанов Е.В. Частота выявления инфекции Clostridium difficile в больничных условиях // Альманах клинической медицины. - 2014. № 33. - С. 71-76
4. Дмитриева Н.В., Ключникова И.А., Шильникова И.И. Clostridium difficile-ассоциированная диарея (обзор литературы) // Сибирский онкологический журнал. - 2014. - № 1 (61). - С. 46-53
5. Захарова Н.В., Филь Т.С. Микробиологические и клинические особенности инфекции Clostridium difficile // Инфекционные болезни. - 2015. - Т. 13, № 3. - С. 81-86
6. Захарова Н.В., Филь Т.С. С. difficile и микробиота: как предупредить, диагностировать и лечить инфекцию // Дневник казанской медицинской школы. - 2014. - Т. 3, № 6. - С. 53-58
7. Ивашкин В.Т., Ющук Н.Д., Маев И.В., Лапина Т.Л., Полуэктова Я.А., Шифрин О.С., Тертычный А.С., Трухманов А.С., Шептулин А.А., Баранская Е.К., Ляшенко О.С., Ивашкин К.В. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению Clostridium difficile-ассоциированной болезни // Российский журнал гастроэнтерологии гепатологии и колопроктологии. - 2016. - № 26 (5). - С. 56-65
8. Карпов И.А., Горбич Ю.Л., Соловей Н.В., Стома И.О. Инфекции, вызванные Clostridium difficile: подходы к диагностике и лечению: учебно-методическое пособие. - Минск: БГМУ, 2014. - 35 с
9. Корнеева О.Н., Ивашкин В.Т. Антибиотикоассоциированный колит: патоморфология, клиника, лечение // Российский журнал гастроэнтерологии гепатологии и колопроктологии. - 2007. - Т. 17, № 3. - С. 65-70
10. Лобзин Ю.В., Захаренко С.М., Иванов Г.А. Современные представления об инфекции Clostridium difficile // Клиническая микробиология и антимикробная терапия. - 2002. - Т. 4, № 3. - С. 200-232
11. Пинчук Т.П., Савельева Н.С., Титова Г.П., Черненькая Т.В., Аванесова В.А., Ярцев П.А. Эндоскопическая диагностика псевдомембранозного колита у реанимационных больных // Экспериментальная и клиническая гастроэнтерология. - 2012. - № 10. - С. 13-16
12. Рациональная фармакотерапия заболеваний органов пищеварения. Руководство для практикующих врачей; 2-е изд., испр. и доп. / Под общ. ред. В.Т. Ивашкина. - М.: Литтерра, 2011. - 848 с
13. Aldrete S.M., Magee M.J., Friedman-Monaco R., Kraft C.S., Chan A., Hutcherson D., Langston A.A., Greenwell B.I., Burd E.M. (2015) Characteristics and antibiotic use associated with short-term risk of Clostridium difficile infection among hospitalized patients. Am J Clin Pathol, 143 (6), 895-900.
14. Bartlett J.C. (2006). Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med, 145 (10), 758-764.
15. Bauer M.P., Notermans D.W., van Benthem B.H., Brazier J.S., Wilcox M.H., Rupnik M., Monnet D.L., van Dissel J.T., Kuijper E.J., ECDIS Study Group. (2011). Clostridium difficile infection in Europe: a hospital-based survey. Lancet, 377, 63-73. doi: 10.1016/S0140-6736(10)61266-4.
16. Benedek O., Podbielski A., Warnke P. (2016). Laboratory experience with the liaison analyzer in the diagnosis of Clostridium difficile-associated diarrhea. Eur J Microbiol Immunol, 6 (3), 215-218.
17. Benes J., Husa P., Nyc O. Diagnosis and therapy of Clostridium difficile infection: Czech national guidelines. Klin Mikrobiol Infekc Lek, 20 (2), 56-66.
18. Bobo L.D., Dubberke E.R., Kollef M. (2016). Clostridium difficile in the ICU: the struggle continues. Chest, 140 (6), 1643-1653.
19. Brien J.A., Caro J.J. (2007). The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol, 28 (11), 1219-1227.
20. Burnham C.A. (2013). Carroll diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. KCClin Microbiol Rev, 26 (3), 604-630.
21. Chang J.Y., Antonopoulos D.A., Kalra A., Tonelli A., Khalife W.T., Schmidt T.M., Young V.B. (2008). Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis, 197 (3), 435-438. doi: 10.1086/525047.
22. Chitnis A.S., Holzbauer S.M., Belflower R.M., Winston L.G., Bamberg W.M., Lyons C., Farley M.M., Dumyati G.K., Wilson L.E., Beldavs Z.G., Dunn J.R., Gould L.H., MacCannell D.R., Gerding D.N., McDonald L.C., Lessa F.C. (2011). Epidemiology of community associated Clostridium difficile infection 2009 through. JAMA Intern Med, 173, 1359-1367.
23. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., Pepin J., Wilcox M.H. (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol, 31 (5), 431-455. doi: 10.1086/651706.
24. Debast S.B., Bauer M.P. (2014). European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect, 20 (2), 45-48.
25. Gerding D.N., Johnson S., Rupnik M., Aktories K. (2014). Clostridium difficile binary toxin CDT: Mechanism, epidemiology, and potential clinical importance. Gut Microbes, 5, 1-13.
26. Gerding D.N., Muto C.A., Owens R.C. (2008). Treatment of Clostridium difficile infection. Clin Infect Dis, 46 (1), 32-42.
27. Gupta A., Khanna S. (2014). Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist, 7, 63-72.
28. Johal S.S., Hammond J., Solomon K., James P.D., Mahida Y.R. (2004). Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut, 53 (5), 673-677.
29. Kazanowski M., Smolarek S., Kinnarney F., Grzebieniak Z. (2014). Clostridium difficile: Epidemiology, diagnostic and therapeutic possibilities - A systematic review. Tech Coloproctol, 18 (3), 223-232.
30. Kelly C.P., La Mont J.T. (2008). Clostridium difficile -more difficult than ever. N Engl J Med, 359 (18), 1932-1940.
31. Khanna S., Pardi D.S. (2014). Clostridium difficile infection: management strategies for a difficult disease. Ther Adv Gastroenterol, 7 (2), 72-86.
32. Knight D.R., Elliott B., Chang B.J., Perkins T.T., Riley T.V. (2015). Diversity and evolution in the genome of clostridium difficile. Clin Microbiol Rev, 28 (3), 721-741. doi: 10.1128/CMR.00127-14.
33. Korman T.M. (2015). Diagnosis and management of Clostridium difficile infection. Semin Respir Crit Care Med, 36 (1), 31-43.
34. Kostic A.D., Xavier R.J., Gevers D. (2015). The microbiome in iflammatory bowel diseases: current status and the future ahead. Gastroenterology, 146 (6), 1489-1499.
35. Kurti Z., Lovasz B.D., Mandel M.D., Csima Z., Golovics P.A., Csako B.D., Mohas A., Gönczi L., Gecse K.B., Kiss L.S., Szathmari M., Lakatos P.L. (2015). Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe. World J Gastroenterol, 21 (21), 6728-6735.
36. Lowy I., Molrine D., Leav B. (2010). Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med, 362, 197-205.
37. Lupse M., Flonta M., Cioara A. (2013). Predictors of first recurrence in Clostridium diffcile-associated disease. A study of 306 patients hospitalized in a Romanian tertiary referral center. J Gastrointestin Liver Dis, 22 (4), 397-403.
38. McFarland L.V. (2006). Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol, 101, 812-822.
39. Miller M.A. (2007). Clinical management of Clostridium difficile-associated disease. Clin Infect Dis, 45, Suppl 2, 122-128.
40. Nelson R.L., Kelsey P., Leeman H., Meardon N., Patel H., Paul K., Rees R., Taylor B., Wood E., Malakun R. (2011) Antibiotic treatment for Clostridium difficile associated diarrhea in adult. Cochrane Database Syst Rev, 9. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21901692. doi: 10.1002/14651858
41. Norman J.M., Handley S.A., Baldridge M.T., Droit L., Liu C.Y., Keller B.C., Kambal A., Monaco C.L., Zhao G., Fleshner P., Stappenbeck T.S., McGovern D.P., Keshavarzian A., Mutlu E.A., Sauk J., Gevers D., Xavier R.J., Wang D., Parkes M., Virgin H.W. (2016). Disease-specific alterations in the enteric virome in inflammatory bowel disease. NIH Public Access, 160 (3), 447-460. doi: 10.1016/j.cell.2015.01.002.
42. Qin J., Li Y., Cai Z., Li S., Zhu J., Zhang F., Liang S., Zhang W., Guan Y., Shen D., Peng Y., Zhang D., Jie Z., Wu W., Qin Y., Xue W., Li J., Han L., Lu D., Wu P., Dai Y., Sun X., Li Z., Tang A., Zhong S., Li X., Chen W., Xu R., Wang M., Feng Q., Gong M., Yu J., Zhang Y., Zhang M., Hansen T., Sanchez G., Raes J., Falony G., Okuda S., Almeida M., LeChatelier E., Renault P., Pons N., Batto J.M., Zhang Z., Chen H., Yang R., Zheng W., Li S., Yang H., Wang J., Ehrlich S.D., Nielsen R., Pedersen O., Kristiansen K., Wang J. (2012). A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature, 490 (7418), 55-60.
43. Russello G., Russo A., Sisto F., Scaltrito M.M., Farina C. (2012). Laboratory diagnosis of Clostridium difficile associated diarrhoea and molecular characterization of clinical isolates. New Microbiol, 35, 307-316.
44. Semenyuk E.G., Laning M.L., Foley J., Johnston P.F., Knight K.L., Gerding D.N., Driks A. (2014). Spore formation and toxin production in Clostridium difficile biofilms. PLoS One, 9 (1), 1-14. doi: 10.1371/journal.pone.0087757
45. Seo G.S. (2013). Clostridium difficile infection: what’s new? In test Res, (11), 1-13.
46. Shah D.N., Aitken S.L., Barragan L.F., Bozorgui S., Goddu S., Navarro M.E., Xie Y., DuPont H.L., Garey K.W. (2016). Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect Elsevier, 93 (3), 286-289. doi: 10.1016/j.jhin.2016.04.004.
47. Slimings C., Riley T.V. (2014). Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother, 69, 881-891
48. Surawicz C.M., Brandt L.J., Binion D.G., Ananthakrishnan A.N., Curry S.R., Gilligan P.H., McFarland L.V., Mellow M., Zuckerbraun B.S. (2013). Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol, 108 (4), 478-498. doi: 10.1038/ajg.2013.4.
49. Turgeon D.K., Novicki T.J., Quick J., Carlson L., Miller P., Ulness B., Cent A., Ashley R., Larson A., Coyle M., Limaye A.P., Cookson B.T., Fritsche T.R. (2003) Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. J Clin Microbiol, 41 (2), 667-670.
50. Videlock E., Cremonini F. (2012) Meta-analysis: probiotics in antibiotic-associated diarrhea. Aliment Pharmacol Ther, 35 (12), 1355-1369.
51. Yoldaş Ö., Altindiş M., Cufali D., Aşik G., Keşli RAu. (2016). A diagnostic algorithm for the detection of Clostridium difficile-associated diarrhea. Balkan Med J, 33 (1), 80-86. doi: 10.5152/balkanmedj.2015.15159.
52. Zhang S., Palazuelos-Munoz S., Balsells E.M., Nair H., Chit A., Kyaw M.H. (2016). Cost of hospital management of Clostridium difficile infection in the United States - a meta-analysis and modelling study. BMC Infect Dis, 16, 1-18.
Review
For citations:
Nikolaeva I.V., Shestakova I.V., Murtazina G.K. Current strategies for diagnosis and treatment of Clostridium difficile-infection (literature review). Acta Biomedica Scientifica. 2018;3(1):34-42. (In Russ.) https://doi.org/10.29413/ABS.2018-3.1.5
Views:
1441
Email this article 
